Paradigm Acquisition | Global IP for the combination of PPS and a Cox-2 inhibitor
Paradigm MD, Paul Rennie, discusses the acquisition of Proteobioactives Pty Ltd and how the access to global IP for the combination of PPS and a Cox-2 inhibitor, builds out Paradigms OA portfolio.
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Paradigm Biopharmaceuticals. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Paradigm Biopharmaceuticals a question about this update.